MacroGenics (NASDAQ:MGNX) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen downgraded shares of MacroGenics (NASDAQ:MGNX – Free Report) from a hold rating to a sell rating in a research report report published on Saturday,Wall Street Zen reports.

Other research analysts have also recently issued research reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MacroGenics in a report on Tuesday, November 3rd. Citigroup began coverage on MacroGenics in a research report on Friday, October 23rd. They set a “positive” rating for the company. Finally, B. Riley Financial lifted their target price on MacroGenics from $9.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, August 17th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, MacroGenics presently has an average rating of “Hold” and a consensus target price of $8.50.

Read Our Latest Analysis on MacroGenics

MacroGenics Stock Down 3.9%

MacroGenics stock traded down $0.09 during midday trading on Friday, hitting $2.20. The company’s stock had a trading volume of 997,828 shares, compared to its average volume of 1,055,111. MacroGenics has a 12 month low of $1.32 and a 12 month high of $5.08. The company has a market capitalization of $140.14 million, a PE ratio of -2.72 and a beta of 1.33. The stock’s 50-day moving average price is $3.33 and its 200-day moving average price is $3.43.

MacroGenics (NASDAQ:MGNX – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.39. The company had revenue of $32.83 million during the quarter, compared to the consensus estimate of $59.14 million. MacroGenics had a negative net margin of 45.37% and a negative return on equity of 223.84%. As a group, equities analysts anticipate that MacroGenics will post -1.14 EPS for the current year.

Insider Activity

In other news, VP Jeffrey Peters sold 31,105 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $4.15, for a total value of $129,085.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Legal & General Group Plc acquired a new stake in MacroGenics during the 2nd quarter worth about $28,000. State of Wyoming grew its stake in MacroGenics by 201.0% during the 3rd quarter. State of Wyoming now owns 7,518 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 5,020 shares in the last quarter. Seven Fleet Capital Management LP purchased a new position in MacroGenics during the 1st quarter valued at about $39,000. Sanders Morris Harris LLC acquired a new position in shares of MacroGenics in the 3rd quarter valued at about $48,000. Finally, Two Sigma Securities LLC acquired a new position in shares of MacroGenics in the 2nd quarter valued at about $63,000. 96.89% of the stock is owned by institutional investors and hedge funds.

MacroGenics Company Profile

(Get Free Report)

MacroGenics, Inc. is a biotechnology company focused on discovering and developing antibody-based medicines, primarily for cancer. Founded in 2000 and headquartered in Rockville, Maryland, the company works on its own drug candidates and collaborates with other pharmaceutical and biotechnology companies. Its research uses antibody-engineering technologies, including platforms designed to engage immune cells against tumors and to deliver therapeutic payloads to cancer cells. MacroGenics’ portfolio has included margetuximab, marketed as Margenza, an antibody treatment approved in the United States for certain patients with HER2-positive metastatic breast cancer.

Recommended Stories

Analyst Recommendations for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.